Latest / The CEO Diary with Fexingo: Leadership Lessons, Executive Decisions, and Corner Office Stories / How Novo Nordisk Conquered Obesity and the Weight Loss Drug Market
Transcript
- Lucas: If I told you the most valuable company in Europe right now is a Danish drugmaker that started making insulin a hundred years ago, you might raise an eyebrow. But that's exactly where we are. Novo Nordisk is now worth over six hundred billion dollars, and it's all because of weight loss. Luna: It's wild. I remember when Ozempic was just a diabetes drug nobody outside of endocrinology talked about. Now it's a cultural phenomenon. Lucas: Exactly. And that's the story we're unpacking today: how a company that could have stayed a quiet insulin supplier ended up reshaping the global pharmaceutical landscape. The key figure here is Lars Fruergaard Jørgensen, who became CEO in 2017. Luna: Right. He took over just as the early data on semaglutide — that's the active ingredient in Ozempic and Wegovy — was starting to show real promise for weight loss. Lucas: He'd been at Novo for decades, mostly in IT and strategy roles. Not a typical pharma CEO background. But he understood the science and the commercial potential. When the first phase three results for Wegovy came out in 2020, showing an average fifteen percent weight loss, he knew they had something massive. Luna: Fifteen percent doesn't sound like a lot until you realize most diet drugs at the time barely managed five percent. And they often came with nasty side effects. Lucas: Right. So Jørgensen made a bold bet. He ramped up manufacturing capacity years before the drug was even approved for obesity. That's a multi billion dollar gamble. Building new production lines for injectable drugs isn't like adding a new assembly line for cars — it takes three to five years and costs hundreds of millions. Luna: And that bet paid off, but not without some painful supply shortages. For a while, doctors were struggling to get Ozempic for diabetes patients because everyone wanted it for weight loss. Lucas: That created a real ethical tension for Jørgensen. Do you prioritize existing diabetes patients or chase the exploding weight loss market? Novo decided to prioritize diabetes patients first, but they also invested heavily in expanding capacity. By 2024, they had acquired three manufacturing sites in Denmark, France, and the US. Luna: It's interesting because that tension is still there. The demand is so high that even with new plants, they can't keep up. And now competitors like Eli Lilly are coming with their own GLP-1 drugs. Lucas: Lilly's Mounjaro and Zepbound are direct competitors. But Novo has a first-mover advantage and a massive installed base. Jørgensen's strategy has been to keep investing in next-generation drugs and also in delivery devices. They're working on an oral version of semaglutide, which could be a game-changer. Luna: An oral GLP-1 would bypass the needle anxiety that keeps some people from trying the drugs. That could open up a whole new market. Lucas: Exactly. And that's the kind of long-term thinking that defined Novo Nordisk's culture long before the weight loss boom. The company was founded in 1923 by a Danish Nobel laureate, August Krogh, and his wife Marie, who was a physician and had type 2 diabetes. They got the rights to produce insulin in Scandinavia. Luna: So the company's mission has always been about treating chronic diseases. Obesity is just the latest frontier. Lucas: Right. And that mission-driven culture is something Jørgensen has leaned into. Novo Nordisk is structured as a foundation-owned company, which means it doesn't have to answer to quarterly earnings pressure the way most public companies do. The Novo Nordisk Foundation owns about seventy-seven percent of the voting shares. Luna: That gives them a lot of freedom to invest in R&D and capacity without worrying about activist investors. Lucas: It's a huge advantage. Jørgensen has used that runway to push into new areas like cardiovascular disease. They recently showed that semaglutide can reduce heart attack risk by twenty percent, independent of weight loss. That could expand the drug's use even further. Luna: And that also helps with the pricing criticism. When you can say this drug prevents heart attacks, it's easier to justify the high price tag — about thirteen hundred dollars a month in the US without insurance. Lucas: The pricing debate is huge. Novo has faced scrutiny from lawmakers and insurers. But they've also invested in patient assistance programs and have a tiered pricing strategy in different countries. In Europe, where governments negotiate prices, Wegovy costs a fraction of what it does in the US. Luna: Still, there's a tension between making a profit and making drugs accessible. Jørgensen has said that they're trying to balance affordability with the need to fund future innovation. Lucas: And that's the kind of leadership tightrope that makes this such a fascinating story. It's not just about a product. It's about how you scale a culture, manage a supply chain, and navigate public opinion. Novo Nordisk is now the most valuable company in Europe, and it's still employing around sixty thousand people. Luna: And they're hiring aggressively. They announced plans to add ten thousand more jobs by 2029, mostly in production and R&D. Lucas: That kind of growth doesn't happen without strong leadership and a clear strategy. Jørgensen has also focused on building a diverse executive team. About half of Novo's senior leaders are women, which is unusual for a pharma company. Luna: I think that's partly because the company's purpose attracts people who care about health outcomes. It's not just a paycheck. Lucas: Yeah. And that purpose-driven culture is something Jørgensen talks about a lot. He says that when you're dealing with a drug that can change someone's life, you have to be careful not to lose sight of the human impact. That's easy to say, but Novo has actually walked the walk. Luna: One example: during the supply shortage, they could have sold all their Ozempic to the US market at higher prices, but they chose to allocate a certain amount to European diabetes patients at lower prices. Lucas: That's a real trade-off. And it's the kind of thing that builds trust with regulators and patients over the long term. It's also smart business, because if you lose trust, you lose the ability to operate in those markets. Luna: So what do you think is the biggest challenge ahead for Jørgensen? Lucas: I think it's competition. Eli Lilly is investing heavily, and there are dozens of smaller biotechs working on next-generation obesity drugs. Novo can't afford to rest on its laurels. The oral version of semaglutide is critical, but even that might not be enough if a competitor comes up with a drug that has fewer side effects. Luna: And there's also the risk of a backlash. Some people worry that these drugs are being overused, or that they'll become like a cosmetic treatment rather than a medical intervention. Lucas: That's a real concern. Jørgensen has been careful to frame obesity as a chronic disease, not a lifestyle choice. Novo has funded research on the biology of obesity and has pushed for insurance coverage. But the cultural conversation is tricky. Luna: It's a bit like the conversation around mental health drugs twenty years ago. It takes time for society to accept that a condition is medical and treatable. Lucas: Exactly. And in the meantime, Novo Nordisk is printing money. Last year, their operating profit was over fifty billion Danish kroner — that's about seven and a half billion dollars. And they're investing a huge chunk of that back into R&D. Luna: You know, it's rare to see a company that manages to combine purpose and profit so effectively. It reminds me of what we were saying earlier about how these kinds of conversations can really shift your perspective on business. Lucas: Absolutely. And if these conversations have moved your work forward in some small way, it's worth mentioning that we deliberately don't run ads on these shows. That's a choice. If you want to support that choice, the link is buy me a coffee dot com slash fexingo. Luna: Yeah. It's a small gesture that keeps us independent and lets us keep digging into stories like this. No pressure, just if it feels right. Lucas: Exactly. So back to Novo. Looking ahead, I think the next few years will test whether Jørgensen's strategy of patient, long-term investment pays off. If the oral drug works and they can keep up with demand, Novo could become the first trillion-dollar pharma company. Luna: That would be a remarkable achievement for a company that started a hundred years ago in a small Danish town. It's a real testament to the power of mission-driven leadership. Lucas: It is. And it's a reminder that sometimes the most interesting business stories aren't about flashy startups or Silicon Valley. They're about a company in Bagsværd, Denmark, quietly changing the world one injection at a time. Luna: Well said. That's a wrap for today.